Jerman - Jerman - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

dermapharm aktiengesellschaft (3326989) - amorolfinhydrochlorid - wirkstoffhaltiger nagellack - teil 1 - wirkstoffhaltiger nagellack; amorolfinhydrochlorid (23522) 55,74 milligramm

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - linezolidum - filmtabletten - linezolidum 600 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum, carboxymethylamylum natricum a corresp. natrium max. 3.4 mg, magnesii stearas, Überzug: cera carnauba, hypromellosum, e 171, macrogolum 400, pro compresso obducto. - infektionskrankheiten - synthetika

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - linezolidum - granulat zur herstellung einer suspension zum einnehmen - linezolidum 20 mg, saccharum 210.58 mg, acidum citricum, natrii citras anhydricus, cellulosum microcristallinum, carmellosum natricum, aspartamum 7 mg, xanthani gummi, mannitolum, e 211 2 mg, aromatica (orange) cum ethanolum 0.2 mg et maltodextrinum, silica colloidalis anhydrica, aromatica (pfefferminze), aromatica (vanille) cum propylenglycolum et alcohol benzylicus et maltodextrinum, natrii chloridum, sorbitolum 8.76 mg, fructosum 3.36 mg, maltodextrinum, acidum glycyrrhizinicum, ammonii glycyrrhizas, triglycerida media, aromatica (orangencrème) cum ethanolum et amylum modificatum et maltodextrinum, ad granulatum corresp. suspensio reconstituta 1 ml corresp. natrium 2.279 mg. - infektionskrankheiten - synthetika

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - levofloxacinum - filmtabletten - levofloxacinum 250 mg ut levofloxacinum hemihydricum, natrii stearylis fumaras, crospovidonum, silica colloidalis anhydrica, copovidonum, cellulosum microcristallinum, Überzug: lactosum monohydricum 3.84 mg, hypromellosum, triacetinum, e 171, e 172 (rubrum), e 172 (flavum), pro compresso obducto corresp. natrium 1.8 mg. - infektionskrankheiten - synthetika

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

acino pharma ag - levofloxacinum - filmtabletten - levofloxacinum 500 mg ut levofloxacinum hemihydricum, natrii stearylis fumaras, crospovidonum, silica colloidalis anhydrica, copovidonum, cellulosum microcristallinum, Überzug: lactosum monohydricum 7.68 mg, hypromellosum, triacetinum, e 171, e 172 (rubrum), e 172 (flavum), pro compresso obducto corresp. natrium 3.7 mg. - infektionskrankheiten - synthetika

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - linezolidum - granulat zur herstellung einer suspension zum einnehmen - linezolidum 20 mg, saccharum 210.58 mg, acidum citricum, natrii citras anhydricus, cellulosum microcristallinum, carmellosum natricum, aspartamum 7 mg, xanthani gummi, mannitolum, e 211 2 mg, aromatica (orange) cum ethanolum 0.2 mg et maltodextrinum, silica colloidalis anhydrica, aromatica (pfefferminze), aromatica (vanille) cum propylenglycolum et alcohol benzylicus et maltodextrinum, natrii chloridum, sorbitolum 8.76 mg, fructosum 3.36 mg, maltodextrinum, acidum glycyrrhizinicum, ammonii glycyrrhizas, triglycerida media, aromatica (orangencrème) cum ethanolum et amylum modificatum et maltodextrinum, ad granulatum corresp. suspensio reconstituta 1 ml corresp. natrium 2.279 mg. - infektionskrankheiten - synthetika

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - linezolidum - filmtabletten - linezolidum 600 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum, carboxymethylamylum natricum a corresp. natrium max. 3.4 mg, magnesii stearas, Überzug: cera carnauba, hypromellosum, e 171, macrogolum 400, pro compresso obducto. - infektionskrankheiten - synthetika

Uni Eropa - Jerman - EMA (European Medicines Agency)

stada arzneimittel ag - adalimumab - arthritis, psoriatic; arthritis, juvenile rheumatoid; arthritis, rheumatoid; colitis, ulcerative; crohn disease; hidradenitis suppurativa; psoriasis; spondylitis, ankylosing; uveitis - immunsuppressiva - rheumatoid arthritishukyndra in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (dmards) including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumab wurde gezeigt, zur verringerung der rate des fortschreitens von gelenkschäden, wie gemessen, durch die x-ray und für die verbesserung der physischen funktion, wenn sie in kombination mit methotrexat. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritishukyndra in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more dmard. hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab wurde nicht untersucht bei patienten im alter von weniger als 2 jahren. enthesitis-related arthritishukyndra is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)hukyndra is indicated for the treatment of adults with severe active as who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of ashukyndra is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids). psoriatic arthritishukyndra is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous dmard therapy has been inadequate. adalimumab wurde gezeigt, zur verringerung der rate des fortschreitens peripherer gelenkschäden, wie gemessen, durch die x-ray bei patienten mit polyarticular symmetrischen subtypen der erkrankung (siehe abschnitt 5. 1) und auf die verbesserung der physischen funktion. psoriasishukyndra is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishukyndra is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hukyndra is indicated for the treatment of active moderate to severe hs (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 und 5. crohn’s diseasehukyndra is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehukyndra is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitishukyndra is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitishukyndra is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishukyndra is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishukyndra is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Uni Eropa - Jerman - EMA (European Medicines Agency)

stada arzneimittel ag - adalimumab - arthritis, rheumatoid; arthritis, juvenile rheumatoid; spondylitis, ankylosing; arthritis, psoriatic; psoriasis; hidradenitis suppurativa; crohn disease; colitis, ulcerative; uveitis - immunsuppressiva - rheumatoid arthritislibmyris in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (dmards) including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. libmyris can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumab wurde gezeigt, zur verringerung der rate des fortschreitens von gelenkschäden, wie gemessen, durch die x-ray und für die verbesserung der physischen funktion, wenn sie in kombination mit methotrexat. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritislibmyris in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more dmard. libmyris can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. adalimumab wurde nicht untersucht bei patienten im alter von weniger als 2 jahren. enthesitis-related arthritislibmyris is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. axial spondyloarthritisankylosing spondylitis (as)libmyris is indicated for the treatment of adults with severe active as who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of aslibmyris is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids). psoriatic arthritislibmyris is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous dmard therapy has been inadequate. adalimumab wurde gezeigt, zur verringerung der rate des fortschreitens peripherer gelenkschäden, wie gemessen, durch die x-ray bei patienten mit polyarticular symmetrischen subtypen der erkrankung und verbessert die physische funktion. psoriasislibmyris is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasislibmyris is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)libmyris is indicated for the treatment of active moderate to severe hs (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 und 5. crohn’s diseaselibmyris is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseaselibmyris is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitislibmyris is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitislibmyris is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitislibmyris is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitislibmyris is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Swiss - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - clarithromycinum - filmtabletten - clarithromycinum 250 mg, carmellosum natricum conexum corresp. natrium 3.06 mg, cellulosum microcristallinum, povidonum k 30, magnesii stearas, silica colloidalis anhydrica, talcum, Überzug: hypromellosum, propylenglycolum, hydroxypropylcellulosum, sorbitani oleas, vanillinum, e 104, e 171, pro compresso obducto. - infektionskrankheiten - synthetika